By Donna Loyle, communications manager, LIMR
Researchers seek to determine if there are any side effects of Keytruda® (pembrolizumab) with or without chemotherapy in treating patients aged 70 and older diagnosed with metastatic, stage 4 non-small cell lung cancer.
Eligible participants are grouped into two study arms:
- Group A receives pembrolizumab IV on day 1. Cycles repeat every 21 or 42 days.
- Group B receives pembrolizumab and the chemotherapies pemetrexed and carboplatin IV on day 1. Cycles for pembrolizumab repeat every 21 or 42 days. Cycles for the chemotherapies repeat every 21 days.
Study # A171901 is approved for all MLH acute care hospitals. For more on this clinical trial, email email@example.com or visit https://www.mainlinehealth.org/research/clinical-trials/a171901